Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 11/20 | 0.44 |
| ▸ | SCN1A | P35498 | 1/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 6/20 | 0.41 |
| ▸ | HTR2A | P28223 | 3/20 | 0.41 |
| ▸ | DRD2 | P14416 | 3/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7352709 | 0.93 | HTR7 (0.45) | DRD4HTR2ADRD2DRD3HTR1A | |
| SCHEMBL7356138 | 0.91 | DRD4 (0.38) | DRD4HTR1AHTR7 | |
| SCHEMBL7346919 | 0.87 | UTS2R (0.42) | DRD4HTR2ADRD2HTR1AHTR7 | |
| SCHEMBL6457611 | 0.87 | SLC6A5 (0.51) | SLC6A5SCN1ASCN5ASCN9ADRD4 | |
| SCHEMBL7346972 | 0.85 | SLC6A5 (0.60) | SLC6A5DRD4HTR2ADRD2 | |
| SCHEMBL7346054 | 0.84 | CNR2 (0.40) | HTR1AHTR7 | |
| SCHEMBL6466592 | 0.80 | HTR7 (0.55) | SLC6A5HTR2ADRD2DRD3HTR1A | |
| SCHEMBL6458101 | 0.79 | HTR7 (0.54) | SLC6A5HTR2ADRD2DRD3HTR1A | |
| SCHEMBL6462598 | 0.79 | HTR7 (0.54) | SLC6A5HTR2ADRD2DRD3HTR1A | |
| SCHEMBL6462987 | 0.78 | HTR7 (0.47) | HTR1AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6307051-B1 | UROKINASE-TYPE PLASMINOGEN ACTIVATOR ANTAGONISTS AND HAVE ANTITUMOR AND ANTIMETASTATIC ACTIVITY. | ROCHE DIAGNOSTICS GMBH (DE) | 2001-10-23 | — | — | US | disclosed |
| EP-1026165-A1 | O-substituted Hydroxycoumaranone derivatives as antitumor and antimetastatic agents | Roche Diagnostics GmbH (DE) | 2000-08-09 | — | — | EP | disclosed |